1. Report Overview
1.1 Global Pre-Filled Injection Devices Market Overview
1.2 Pre-Filled Injectable Devices Market Segmentation
1.3 Top Pre-Filled Injectable Devices Market: An Overview
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Introduction to Pre-Filled Injectable Devices
2.1 What are Pre-Filled Injectable Devices?
2.2 Classification of Companies in the Pre-Filled Injectable Devices Market
2.2.1 Pen Injectors and Autoinjectors
2.2.2 Benefits and Weaknesses of Pre-Filled Injectors
2.3 The Pre-Filled Injection Devices Market 2017-2028
2.4 Contract Manufacturing as a Sector of the Pre-Filled Injectable Devices Market
2.5 Demand on the Western Market is the Highest
2.6 Key Trends in the Pre-Filled Injection Device Market 2017-2028
2.6.1 Increased Market Consolidation
2.6.2 Increased Development of Biologics and Biosimilars
2.6.3 Rise in At Home Care
2.6.4 Greater Demands for Safety Leading Innovation
2.6.5 Threat from Other Drug Delivery Technologies

3. Leading Companies in the Pre-Filled Syringes Manufacturing Market 2017-2028
3.1 Becton, Dickinson, & Co (BD)
3.1.1 BD: Broad Portfolio of Syringe Products
3.1.1.1 BD Hypak: The First Glass Pre-Filled Syringe Worldwide
3.1.1.2 BD Sterifill
3.1.1.3 BD Neopak
3.1.1.4 BD Hylok for Viscous and Intravenous Drugs
3.1.1.5 BD Uniject on the Emerging Market
3.1.1.6 BD Physioject Autoinjector
3.1.1.7 BD Nano 4mm Pen Needles
3.1.1.8 BD Pen Injectors: BD Liquid Dry Injector and BD Reusable Pen
3.1.1.9 BD Vystra Disposable Pen
3.1.1.10 BD Proprietary Syringe Safety Systems
3.1.2 R&D - New Product Launches Planned
3.1.3 BD Acquires C.R. Bard
3.1.4 BD’s Pre-Filled Injection Historical Revenue 2016-2017
3.1.5 Major Acquisitions and Focus on Core Competencies
3.1.6 BD’s Main Strategic Goals
3.1.7 BD: Trend for Strategic Partnering
3.1.8 BD SWOT Analysis, 2018-2028
3.1.8.1 Collaboration and Expansion: Strategies for Growth and Rebranding
3.1.8.2 BD Medical Revenue Forecast 2017-2028
3.2 Gerresheimer
3.2.1 Pre-Filled Syringe Manufacture at Gerresheimer
3.2.1.1 RTF (Ready-To-Fill) Glass Syringes at Gerresheimer
3.2.1.2 ClearJect RTF Plastic Syringes at Gerresheimer
3.2.1.3 New German-made RTF ClearJect Syringe Combines the RTF Concept with Plastic
3.2.2 Pen Injector Manufacture at Gerresheimer
3.2.3 Gerresheimer Historical Revenue 2016-2017
3.2.4 Strategic Acquisitions and Collaborations– Sensile Medical and West Pharmaceuticals
3.2.5 Strategic Sale of Glass Tubing Business: Company Focus on Medical Devices and Primary Packaging
3.2.6 Strong Growth in the Plastics and Devices Division with a Focus on Modernisation
3.2.7 Standardisation as a Strategy
3.2.8 Gerresheimer SWOT Analysis, 2018-2028
3.2.8.1 Rapid Growth Planned for Emerging Markets
3.2.8.2 Gerresheimer is Well-Placed for Biologics Growth and More Stringent Regulatory Changes
3.2.8.3 Gerresheimer Plastics & Devices Market Revenue Forecast 2017 to 2028
3.3 Schott
3.3.1 Schott Markets Glass and Plastic Pre-Filled Syringes
3.3.1.1 SyriQ BioPure Launch for Sensitive Drugs
3.3.1.2 Glass Syringes at Schott: Forma 3s and syriQ
3.3.1.3 TopPac Polymer Syringes
3.3.1.4 InJentle Syringes for Sensitive Drug Products
3.3.1.5 Other New Innovations at Schott
3.3.2 Schott Historical Revenue
3.3.3 Expansion in Developed and Emerging Markets
3.3.3.1 Growth in the Emerging Market
3.3.4 Schott SWOT Analysis, 2018-2028
3.3.4.1 Schott’s Emerging Market Strategy
3.4 Nipro Medical Corporation
3.4.1 Overview of Nipro’s Pre-Filled Syringe Portfolio
3.4.2 New Products at Nipro
3.4.3 Nipro is Expanding Globally
3.4.4 Nipro SWOT Analysis, 2018-2028
3.4.4.1 Responding to Rising Diabetes Incidence
3.5 Stevanato Group/Ompi
3.5.1 Ompi Markets Glass Pre-Filled Syringes and Cartridges
3.5.1.1 EZ-Fill Syringe
3.5.1.2 Extra High Quality (XQ) Syringes
3.5.1.3 Acquisitions Collaborations and Innovations at Ompi
3.5.2 Focused on Growth for Cartridges and Vials Manufacturing Especially in Emerging Markets
3.5.3 Ompi SWOT Analysis, 2018-2028
3.5.3.1 Ompi’s Products for the Biologics Market
3.5.3.2 Investing to Expand Capacity and Deal with Increasing Demand
3.6 Pre-Filled Syringe Manufacturers: Competitor Analysis 2018 to 2028
3.6.1 The Need for Advanced Safety Systems
3.6.2 Meeting the Demands of Biologics and Biosimilar Developers
3.6.3 Product Portfolio Diversity
3.6.4 What Demand is there in Emerging Markets?
3.7 High Barriers to Market Entry Will Limit Competition to 2028
3.8 Other Manufacturers of Interest in this Market
3.8.1 Weigao Group Pharmaceutical Packaging Products Company
3.8.1.1 Weigao’s Historical Revenue 2015-2017
3.8.1.2 Weigao Pre-Filled Syringes Revenue Forecast 2017-2028
3.8.2 Roselabs Group

4. Leading Companies in the Pre-Filled Injectable Components Manufacturing Market
4.1 Aptar Stelmi is a Pharma Packaging Specialist
4.1.1 Aptar Stelmi’s Pre-Fillwed Syringe Components
4.1.1.1 Aptar Stelmi’s Rigid Needle Shields
4.1.2 Aptar: Strategically Increasing Market Access to the Autoinjector Market
4.1.3 Aptar Stelmi’s Expansion and Innovations
4.1.4 Aptar Stelmi’s Historical Revenue 2015-2017
4.1.5 Aptar Stelmi SWOT Analysis, 2018-2028
4.1.5.1 Regional Expansion is Important for Continued Growth
4.1.6 Aptar Stelmi Revenue Forecast 2017-2028
4.2 Dätwyler Holding
4.2.1 Dätwyler’s Pre-Filled Syringe Components
4.2.1.1 Omniflex Coating: An Alternative to Silicone Oil
4.2.2 Demand from Insulin Manufacturers Drives Revenue Growth 2015-2017
4.2.3 Dätwyler is Focused on Strategic Acquisition and Expansion
4.2.4 Growth in Emerging Markets
4.2.5 Dätwyler SWOT Analysis, 2018-2028
4.2.6 Dätwyler Healthcare Revenue Forecast 2017-2028
4.3 West Pharmaceutical Services
4.3.1 West Manufactures Syringes and Syringe Components
4.3.1.1 Daikyo Crystal Zenith: Licensed from Daikyo Seiko
4.3.1.2 MixJect for Lyophilised Drugs
4.3.1.3 West’s Self-Injection Systems
4.3.1.4 West Markets Three Safety Systems
4.3.1.5 Innovation and Investment at West
4.3.2 Recent Financial Performance
4.3.3 Collaborations with Big Pharma for Product Development
4.3.4 Expansion at West
4.3.5 West SWOT Analysis, 2018-2028
4.3.6 West Pharmaceutical Revenue Forecast 2017-2028
4.4 Pre-Filled Syringe Component Manufacturers: Competitor Analysis 2018-2028
4.4.1 How Can Component Manufacturers React to Increased Safety Demands?
4.4.2 Other Manufacturers of Interest in this Market
4.4.2.1 Tip-top: Three Safety Products for Pre-Filled Syringes
4.4.2.2 Nemera: Formed from Rexam’s Sale of Healthcare Division
4.4.3 Entering the Autoinjector Market
4.4.4 Component Manufacturers Following Pre-Filled Syringe Manufacturers to Emerging Markets

5. Leading Companies in the Pen Injector and Autoinjector Manufacturing Market 2018-2028
5.1 Haselmeier
5.1.1 Haselmeier Markets Six Injection Systems
5.1.1.1 Axis Pen Systems
5.1.1.2 i-Pen: Haselmeier’s Insulin Pen Injector
5.1.2 Company Growth in Germany and India
5.1.3 Haselmeier SWOT Analysis, 2018-2028
5.2 Owen Mumford
5.2.1 Autoinjector and Pen Injector Overview
5.2.1.1 Autoject
5.2.1.2 Autopen
5.2.1.3 SimpleJect: Designed for RA Patients
5.2.2 Innovative Products to Drive Growth
5.2.3 Expanding in Established and New Markets
5.2.4 Owen Mumford SWOT Analysis 2018-2028
5.3 SHL Group
5.3.1 SHL Manufactures a Broad Range of Injection Devices
5.3.1.1 DAI Autoinjectors
5.3.2 SHL Group Continues to Grow in Taiwan
5.3.3 SHL Group SWOT Analysis, 2018-2028
5.4 Ypsomed
5.4.1 Product Portfolio
5.4.1.1 YpsoPen
5.4.1.2 ServoPen
5.4.1.3 UnoPen
5.4.1.4 LyoTwist Injectors for Lyophilised Drugs
5.4.1.5 Ypsomed Markets Two Autoinjectors
5.4.1.6 Expansion at Ypsomed: Current and Future Plans
5.4.2 Ypsomed: Financial Performance 2015-2017
5.4.3 A Focus on Diabetes
5.4.4 Ypsomed SWOT Analysis, 2018-2028
5.4.5 Ypsomed Revenue Forecast 2017-2028
5.5 Pen Injector and Autoinjector Manufacturers: Competitor Analysis 2017-2028
5.5.1 A Competitive Market 2018-2028
5.5.2 Other Manufacturers of Interest in this Market
5.5.2.1 Bespak Injectables
5.5.3 How Are Companies Differentiating Their Autoinjectors?
5.5.4 Rising Demand in At-Home Care
5.5.4.1 Specific Demands in RA and MS
5.5.5 Contract Manufacturing for Autoinjectors

6. Leading Companies in the Contract Pre-Filled Injectable Devices Manufacturing Market 2017-2028
6.1 Catalent is the World’s Largest CMO
6.1.1 Pre-Filled Syringe Contract Manufacturing Capabilities
6.1.2 Catalent Offers an Autoinjector
6.1.3 Innovations at Catalent
6.1.4 Catalent Pharma Solutions: Financial Performance 2015-2017
6.1.5 Expanding Filling Capacity for Clinical Trial Materials
6.1.6 Acquisitions and Collaborations
6.1.7 Catalent SWOT Analysis 2018-2028
6.1.8 Catalent Biologics and Speciality Drug Delivery Revenue Forecast 2017-2028
6.2 Vetter Pharmaceutical
6.2.1 Vetter is an Injectable Manufacturing Specialist
6.2.2 Vetter’s Ten-Year Expansion Plan
6.2.3 New Services and Collaborations
6.3 The Competitive Outlook for Leading CMOs in the Market 2018-2028
6.3.1 Biologics, Lyophilisation, and Dual-Chamber Syringes
6.3.2 An Increasingly Competitive Market
6.3.3 Important of Keeping Up with Regulations
6.4 Other Pre-Filled Syringe Contract Manufacturers 2016
6.4.1 Laboratorios Farmacéuticos ROVI
6.4.1.1 ROVI CM’s Pre-Filled Syringe Capabilities
6.4.2 Boehringer Ingelheim

7. Conclusions
7.1 Outlook for the Pre-Filled Injection System Market 2018-2028
7.2 Outlook for Leading Pre-Filled Injection System Manufacturers 2018-2028
7.2.1 How Will Leading Companies’ Revenues Grow to 2028?
7.3 The Future of the Pre-Filled Medical Devices Market

Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain report evaluation form

List of Tables
Table 2.1 Total Pre-Filled Device Manufacturing Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2028
Table 2.2 Pre-Filled Injection Device Market by Region, 2017
Table 2.3 Pre-Filled Injection Device Market: STEP Analysis, 2017-2028
Table 2.4 Selected Recent Acquisitions in the Pre-Filled Injection Devices Industry, 2014-2018
Table 3.1 BD Overview, 2018
Table 3.2 BD Revenue by Division ($m), 2017
Table 3.3 BD Historical Revenue by Division ($m), AGR (%), 2016-2017
Table 3.4 Medical Division Revenue ($m), 2016-2017
Table 3.5 BD: Pharmaceutical Systems Revenue ($m), AGR (%), CAGR (%), 2015-2017
Table 3.6 BD Pre-Filled Injection Devices: SWOT Analysis, 2018-2028
Table 3.7 BD Pharmaceutical Systems Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2028
Table 3.8 Gerresheimer: Employees by Region, 2017
Table 3.9 Gerresheimer Overview, 2018
Table 3.10 Gerresheimer: Revenue by Division ($m), AGR (%), 2016-2017
Table 3.11 Gerresheimer Pre-Filled Injection Devices: SWOT Analysis, 2018-2028
Table 3.12 Gerresheimer Plastics and Devices: Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2028
Table 3.13 Schott Overview, 2018
Table 3.14 Schott Revenue ($m), AGR (%), CAGR (%), 2015-2017
Table 3.15 Schott Pre-Filled Injection Devices: SWOT Analysis, 2018-2028
Table 3.16 Nipro Overview, 2018
Table 3.17 Nipro Revenue ($m), AGR (%), CAGR (%), 2015-2017
Table 3.19 Nipro Pre-Filled Injection Devices: SWOT Analysis, 2018-2028
Table 3.18 Stevanato Group/Ompi Overview, 2018
Table 3.20 Ompi Pre-Filled Injection Devices: SWOT Analysis, 2018-2028
Table 3.21 Pre-Filled Syringes: Leading Product Comparisons, 2018
Table 3.22 Leading Pre-Filled Syringe Manufacturers: Comparative Product Ranges, 2018
Table 3.23 Weigao Group Pharmaceutical Packaging Products Company Overview, 2016
Table 3.24 Weigao: Pre-Filled Syringes Revenue ($m), AGR (%), CAGR (%), 2015-2017
Table 3.25 Weigao: Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2028
Table 3.26 Roselabs Group Overview, 2018
Table 4.1 Aptar Stelmi Overview, 2018
Table 4.2 Aptar Stelmi – Pharma Injectables: Revenue ($m), AGR (%), CAGR (%), 2015-2017
Table 4.3 Aptar Stelmi Pre-Filled Injection Devices: SWOT Analysis, 2018-2028
Table 4.4 Aptar Stelmi: Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2028
Table 4.5 Dätwyler Overview, 2018
Table 4.6 Dätwyler: Sealing Solutions Revenue ($m), AGR (%), CAGR (%), 2015-2017
Table 4.7 Dätwyler Pre-Filled Injection Devices: SWOT Analysis, 2018-2028
Table 4.8 Dätwyler- Sealing Solutions: Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2028
Table 4.9 West Pharmaceutical Services Overview, 2018
Table 4.10 West: Selected Pharmaceutical Industry Partners, 2018
Table 4.11 West: Revenue by Division ($m), 2015-2017
Table 4.12 West Pre-Filled Injection Devices: SWOT Analysis, 2018-2028
Table 4.13 West Pharmaceuticals: Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2028
Table 4.14 Tip-top Overview, 2018
Table 4.15 Nemera Overview, 2018
Table 5.1 Haselmeier Overview, 2018
Table 5.2 Selected Partners for the i-Pen, 2018
Table 5.3 Haselmeier Pre-Filled Injection Devices: SWOT Analysis, 2018-2018
Table 5.4 Owen Mumford Overview, 2018
Table 5.5 Selected Autoject Range Products, 2018
Table 5.6 Owen Mumford Pre-Filled Injection Devices: SWOT Analysis, 2018 to 2028
Table 5.7 SHL Group Overview, 2018
Table 5.8 SHL Group: Pen Injectors and Autoinjectors, 2017
Table 5.9 SHL Group Pre-Filled Injection Devices: SWOT Analysis, 2018-2028
Table 5.10 Ypsomed Overview, 2018
Table 5.11 Ypsomed: Pen Injectors and Autoinjectors, 2017
Table 5.12 Selected Pharmaceutical Partners for Ypsomed’s Pen Injectors, 2018
Table 5.13 LyoTwist Injectors Available, 2018
Table 5.14 Ypsomed: Revenue by Division ($m), CAGR (%), 2015-2017
Table 5.15 Ypsomed Pre-Filled Injection Devices: SWOT Analysis, 2018-2028
Table 5.16 Ypsomed Delivery Devices: Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2028
Table 5.17 Pen Injectors: Selected Product Comparisons, 2018
Table 5.18 Autoinjectors: Selected Product Comparisons, 2018
Table 5.19 Selected Other Pen Injector and Autoinjector Manufacturers, 2017
Table 5.20 Bespak Injectables Overview, 2017
Table 6.1 Catalent Overview, 2018
Table 6.2 Catalent: Employees by Region, 2018
Table 6.3 Catalent: Revenue by Division ($m), CAGR (%), 2016-2018
Table 6.4 Catalent Pre-Filled Injection Devices: SWOT Analysis, 2018-2028
Table 6.5 Catalent Biologics and Speciality Drug Delivery Division: Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2028
Table 6.6 Vetter Pharma Overview, 2018
Table 6.7 Leading Pre-Filled Syringe CMOs: Company Comparison, 2018
Table 6.8 Laboratorios Farmacéuticos ROVI Overview, 2018
Table 6.9 Laboratorios Farmacéuticos ROVI: Revenue ($m), AGR (%), CAGR (%), 2015-2017
Table 6.10 Boehringer Ingelheim Overview, 2018

List of Figures
Figure 1.1 Global Pre-Filled Injectable Devices Market Segmentation Overview, 2018
Figure 2.1 Total Pre-Filled Device Manufacturing Market Forecast: Revenues ($m), 2017-2028
Figure 2.2 Pre-Filled Injection Device Market by Region, 2015
Figure 3.1 BD Revenue by Division ($m), 2017
Figure 3.2 BD Historical Revenue by Division ($m), 2016-2017
Figure 3.3 BD: Pharmaceutical Systems Revenue ($m), 2015-2017
Figure 3.4 BD Pharmaceutical Systems Revenue Forecast ($m), 2017-2028
Figure 3.5 Gerresheimer: Employees by Region, 2017
Figure 3.6 Gerresheimer: Revenue by Division ($m), 2016-2017
Figure 3.7 Gerresheimer Plastics and Devices: Revenue Forecast ($m), 2017-2028
Figure 3.8 Schott Revenue ($m), 2015-2017
Figure 3.9 Nipro Revenue ($m), 2015-2017
Figure 3.10 Weigao: Pre-Filled Syringes Revenue ($m), 2015-2017
Figure 3.11 Weigao: Revenue Forecast ($m), 2017-2028
Figure 4.1 Aptar Stelmi – Pharma Injectables: Revenue ($m), 2015-2017
Figure 4.2 Aptar Stelmi: Revenue Forecast ($m), 2017-2028
Figure 4.3 Dätwyler: Sealing Solutions Revenue ($m), 2015-2017
Figure 4.4 Dätwyler Healthcare: Revenue Forecast ($m), 2017-2028
Figure 4.5 West: Revenue by Division ($m), 2015-2017
Figure 4.6 West Pharmaceuticals: Revenue Forecast ($m), 2017-2028
Figure 5.1 Ypsomed: Revenue by Division ($m), 2015-2017
Figure 5.2 Ypsomed Delivery Devices: Revenue Forecast ($m), 2017-2028
Figure 6.1 Catalent: Employees by Region, 2017
Figure 6.2 Catalent: Revenue by Division ($m), 2016-2018
Figure 6.3 Catalent Biologics and Speciality Drug Delivery Division: Revenue Forecast ($m), 2017-2028
Figure 6.4 Laboratorios Farmacéuticos ROVI: Revenue ($m), 2015-2017